These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 7662849)

  • 21. On the bioavailability of oral chondroitin sulfate formulations: proposed criteria for bioequivalence studies.
    Vergés J; Castañeda-Hernández G
    Proc West Pharmacol Soc; 2004; 47():50-3. PubMed ID: 15633611
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic analysis of bioequivalence trials: implications for sex-related issues in clinical pharmacology and biopharmaceutics.
    Chen ML; Lee SC; Ng MJ; Schuirmann DJ; Lesko LJ; Williams RL
    Clin Pharmacol Ther; 2000 Nov; 68(5):510-21. PubMed ID: 11103754
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A simple numerical approach towards improving the two one-sided test for average bioequivalence.
    Cao L; Mathew T
    Biom J; 2008 Apr; 50(2):205-11. PubMed ID: 18383447
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Biological availability of gastric juice-resistant coated diclofenac preparations. 1. Bioavailability study following a single administration of a multiple-unit formulation in comparison with a single-unit formulation].
    Scheidel B; Blume H; Walter K; von Nieciecki A; Babej-Dölle RM
    Arzneimittelforschung; 1993 Nov; 43(11):1211-5. PubMed ID: 8292067
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Examining outlying subjects and outlying records in bioequivalence trials.
    Wang W; Chow SC
    J Biopharm Stat; 2003 Feb; 13(1):43-56. PubMed ID: 12635902
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discussion of individual bioequivalence by M.-L. Chen.
    Gould AL
    J Biopharm Stat; 1997 Mar; 7(1):23-9. PubMed ID: 9056584
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New bioequivalence studies: individual bioequivalence and population bioequivalence.
    Nakai K; Fujita M; Ogata H
    Yakugaku Zasshi; 2000 Nov; 120(11):1201-8. PubMed ID: 11190205
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bayesian modeling of multivariate average bioequivalence.
    Ghosh P; Gönen M
    Stat Med; 2008 Jun; 27(13):2402-19. PubMed ID: 18095275
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tests for individual and population bioequivalence based on generalized p-values.
    McNally RJ; Iyer H; Mathew T
    Stat Med; 2003 Jan; 22(1):31-53. PubMed ID: 12486750
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bioavailability and bioequivalence of two oral formulations of alendronate sodium 70 mg: an open-label, randomized, two-period crossover comparison in healthy Korean adult male volunteers.
    Rhim SY; Park JH; Park YS; Lee MH; Kim DS; Shaw LM; Yang SC; Kang JS
    Clin Ther; 2009 May; 31(5):1037-45. PubMed ID: 19539104
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A distribution-free procedure for the statistical analysis of bioequivalence studies.
    Hauschke D; Steinijans VW; Diletti E
    Int J Clin Pharmacol Ther Toxicol; 1992; 30 Suppl 1():S37-43. PubMed ID: 1601530
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Statistical aspects of comparative bioavailability trials.
    Westlake WJ
    Biometrics; 1979 Mar; 35(1):273-80. PubMed ID: 583027
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative crossover, randomized, open-label bioequivalence study on the bioequivalence of two formulations of thioctic acid in healthy volunteers.
    Mignini F; Streccioni V; Tomassoni D; Traini E; Amenta F
    Clin Exp Hypertens; 2007 Nov; 29(8):575-86. PubMed ID: 18058482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bioequivalence and intrasubject variability.
    Liu JP
    J Biopharm Stat; 1991; 1(2):205-19. PubMed ID: 1844697
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bioavailability of two oral formulations of a single dose of levofloxacin 500 mg: an open-label, randomized, two-period crossover comparison in healthy Mexican volunteers.
    Galan-Herrera JF; Poo JL; Rosales-Sanchez O; Fuentes-Fuentes E; Cariño L; Burke-Fraga V; Namur S; Parra MG
    Clin Ther; 2009 Aug; 31(8):1796-803. PubMed ID: 19808138
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Individual bioequivalence--a European perspective.
    Steinijans VW; Hauschke D
    J Biopharm Stat; 1997 Mar; 7(1):31-4. PubMed ID: 9056585
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bioequivalence of two levothyroxine tablet formulations without and with mathematical adjustment for basal thyroxine levels in healthy Argentinian volunteers: a single-dose, randomized, open-label, crossover study.
    Di Girolamo G; Keller GA; de Los Santos AR; Schere D; Gonzalez CD
    Clin Ther; 2008 Nov; 30(11):2015-23. PubMed ID: 19108789
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The assessment of individual and population bioequivalence.
    Chinchilli VM
    J Biopharm Stat; 1996 Mar; 6(1):1-14. PubMed ID: 8838775
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Bioavailability of two verapamil formulations following repeated administration in steady-state conditions. An open, two-period, crossover study].
    Heintz B; Müller A; Lenhard G; Schütz M; Hutt HJ
    Arzneimittelforschung; 1996 Nov; 46(11):1060-3. PubMed ID: 9065315
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Applying multilevel models in evaluation of bioequivalence (I)].
    Liu QL; Shen ZZ; Chen F; Li XS; Yang M
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Dec; 30(12):1302-6. PubMed ID: 20193320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.